Sarcoma  >>  Aplidin (plitidepsin)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Aplidin (plitidepsin) / PharmaMar, Roche
NCT01876043: Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial

Terminated
2
24
Europe
plitidepsin
Institut Bergonié, Ministry of Health, France, PharmaMar
Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma
04/15
04/15
2009-010980-18: Efficacité et Tolérance de la Plitidepsine chez les patients souffrant d’un liposarcome dédifférencié (DLPS) avancé, non opérable ou métastatique, en rechute/réfractaire : Une étude exploratoire multicentrique de phase II.

Ongoing
2
35
Europe
APLIDIN (plitidepsin),
Pharma Mar, S.A.
DEDIFFERENTIATED LIPOSARCOMA (DLPS)
 
 

Download Options